Normington, Charmaine https://orcid.org/0000-0002-3241-8642
Moura, Ines B. https://orcid.org/0000-0002-3019-7196
Bryant, Jessica A. https://orcid.org/0000-0001-8958-4345
Ewin, Duncan J.
Clark, Emma V.
Kettle, Morgan J.
Harris, Hannah C. https://orcid.org/0000-0001-7575-0752
Spittal, William
Davis, Georgina
Henn, Matthew R. https://orcid.org/0000-0001-8734-5797
Ford, Christopher B.
Wilcox, Mark H.
Buckley, Anthony M. https://orcid.org/0000-0002-2790-0717
Funding for this research was provided by:
Rosetrees Trust (M636, M636, M636)
Industrial funding provided Seres Therapeutics
Article History
Received: 28 February 2020
Accepted: 10 December 2020
First Online: 5 February 2021
Competing interests
: M.H.W. has received honoraria for consultancy work, financial support to attend meetings and research funding from Astellas, AstraZeneca, Abbott, Actelion, Alere, AstraZeneca, Bayer, bioMérieux, Cerexa, Cubist, Da Volterra, Durata, Merck, Nabriva Therapeutics plc, Pfizer, Qiagen, Roche, Seres Therapeutics Inc., Synthetic Biologics, Summit and The Medicines Company. I.B.M. has received support to attend meetings from Techlabs Inc. A.M.B. has received financial support to attend meetings and research funding from Seres Therapeutics Inc., Motif Biosciences plc., Nabriva Therapeutics plc, Tetraphase Pharmaceuticals and Hayashibara Co. Ltd. All other authors: none to declare.